UY37842A - Inhibidores de mcl-1 macrocíclicos y métodos de uso - Google Patents

Inhibidores de mcl-1 macrocíclicos y métodos de uso

Info

Publication number
UY37842A
UY37842A UY0001037842A UY37842A UY37842A UY 37842 A UY37842 A UY 37842A UY 0001037842 A UY0001037842 A UY 0001037842A UY 37842 A UY37842 A UY 37842A UY 37842 A UY37842 A UY 37842A
Authority
UY
Uruguay
Prior art keywords
mcl
methods
macrocyclic inhibitors
formula
compounds
Prior art date
Application number
UY0001037842A
Other languages
English (en)
Inventor
Dominique Potin
R Kunzer Aaron
S Judd Andrew
J Souers Andrew
Anthony Mastracchio
Cheng Ji
Chunqiu Lai
M Sullivan Gerard
Zhu Gui-Dong
Jane Gong
A Teske Jesse
D Wendt Michael
Patrick Brady
Roberto Risi
Wilfried Braje
Xiaohong Song
Tao Zhi-Fu
George Doherty
Fabrice Guillier
Frauke Pohlki
D Pennig Thomas
Yiyun Yu
Andreas Kling
Katja Jantos
Yujia Dai
Xilu Wang
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of UY37842A publication Critical patent/UY37842A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona compuestos de Fórmula (I) ,en donde A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, e Y tienen cualquiera de los valores definidos en la memoria descriptiva, y sales farmacéuticamente aceptables de los mismos, que sean útiles como agentes para el tratamiento de enfermedades y afecciones, incluido el cáncer. También se proporcionan composiciones farmacéuticas que comprenden compuestos de Fórmula (I).
UY0001037842A 2017-08-15 2018-08-15 Inhibidores de mcl-1 macrocíclicos y métodos de uso UY37842A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762545836P 2017-08-15 2017-08-15
US201762555470P 2017-09-07 2017-09-07

Publications (1)

Publication Number Publication Date
UY37842A true UY37842A (es) 2019-03-29

Family

ID=65360041

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037842A UY37842A (es) 2017-08-15 2018-08-15 Inhibidores de mcl-1 macrocíclicos y métodos de uso

Country Status (10)

Country Link
US (5) US20200255451A1 (es)
EP (2) EP3668503A4 (es)
JP (2) JP2020531436A (es)
CN (2) CN112533598A (es)
AU (2) AU2018317836A1 (es)
BR (2) BR112020003163A2 (es)
CA (2) CA3073113A1 (es)
TW (1) TW201920204A (es)
UY (1) UY37842A (es)
WO (2) WO2019035899A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3073114A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
CA3073112A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
BR112020003163A2 (pt) * 2017-08-15 2020-09-15 AbbVie Deutschland GmbH & Co. KG inibidores macrocíclicos de mcl-1 e métodos de uso
CN114144230B (zh) 2019-03-15 2024-04-23 弗尔康医疗公司 作为eed和prc2调节剂的大环唑并吡啶衍生物
JOP20210289A1 (ar) 2019-05-20 2023-01-30 Servier Lab مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها
WO2021067827A1 (en) * 2019-10-03 2021-04-08 California Institute Of Technology Mcl1 inhibitors and uses thereof
IL303079A (en) 2020-11-24 2023-07-01 Novartis Ag Antibody-drug conjugates inhibiting MCL-1 and methods of using them
CN112778142B (zh) * 2021-01-11 2023-03-28 北京金城泰尔制药有限公司沧州分公司 比索洛尔游离碱的制备方法
WO2022216945A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Macrocyclic mcl1 inhibitors and uses thereof
EP4351657A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CA3222269A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
AR129380A1 (es) 2022-05-20 2024-08-21 Novartis Ag Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
CN115093365B (zh) * 2022-07-25 2023-07-25 沈阳药科大学 一种雷芬那辛的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014627B (zh) * 2008-04-30 2014-10-29 国家卫生研究院 作为极光激酶抑制剂的稠合双环嘧啶化合物
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG11201805838UA (en) * 2016-04-22 2018-11-29 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer
CA3073112A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
CA3073114A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
BR112020003163A2 (pt) * 2017-08-15 2020-09-15 AbbVie Deutschland GmbH & Co. KG inibidores macrocíclicos de mcl-1 e métodos de uso

Also Published As

Publication number Publication date
TW201920204A (zh) 2019-06-01
EP3668503A1 (en) 2020-06-24
AU2018317828A1 (en) 2020-04-02
BR112020003163A2 (pt) 2020-09-15
US20190055264A1 (en) 2019-02-21
EP3668504A4 (en) 2021-05-05
US20200010480A1 (en) 2020-01-09
US20200255451A1 (en) 2020-08-13
US20220259226A1 (en) 2022-08-18
WO2019035914A1 (en) 2019-02-21
WO2019035899A1 (en) 2019-02-21
AU2018317836A1 (en) 2020-03-19
CA3073113A1 (en) 2019-02-21
US20210292339A1 (en) 2021-09-23
CN112739343A (zh) 2021-04-30
BR112020003130A2 (pt) 2020-10-13
WO2019035914A8 (en) 2019-09-19
CA3073108A1 (en) 2019-02-21
JP2020531427A (ja) 2020-11-05
JP2020531436A (ja) 2020-11-05
CN112533598A (zh) 2021-03-19
EP3668503A4 (en) 2021-04-07
EP3668504A1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
UY37842A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
UY37843A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
UY37844A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
UY39630A (es) Inhibidores de bromodominios
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
UY37205A (es) Inhibidores de bromodominios
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY36308A (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2016007440A (es) Inhibidores del bromodominio.
UY36123A (es) Derivados de carboxamida
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
ECSP18056196A (es) Derivados de indano
CL2016002870A1 (es) Derivados bicíclicos y composición farmacéutica que incluye los mismos
UY36958A (es) Compuestos para administración intracelular
CU20160170A7 (es) Derivados de carboxamida
TR201900156T4 (tr) Tüberküloz ve ilgili hastalıkların tedavisi için kinolil hidrazonlar.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231110